Logo image of HCAT

HEALTH CATALYST INC (HCAT) Stock Fundamental Analysis

NASDAQ:HCAT - Nasdaq - US42225T1079 - Common Stock - Currency: USD

5.23  -0.16 (-2.97%)

After market: 5.23 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to HCAT. HCAT was compared to 39 industry peers in the Health Care Technology industry. HCAT has a bad profitability rating. Also its financial health evaluation is rather negative. HCAT has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

HCAT had positive earnings in the past year.
In the past year HCAT has reported a negative cash flow from operations.
HCAT had negative earnings in each of the past 5 years.
HCAT had a negative operating cash flow in each of the past 5 years.
HCAT Yearly Net Income VS EBIT VS OCF VS FCFHCAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

With a decent Return On Assets value of -9.73%, HCAT is doing good in the industry, outperforming 70.27% of the companies in the same industry.
With a decent Return On Equity value of -22.29%, HCAT is doing good in the industry, outperforming 67.57% of the companies in the same industry.
Industry RankSector Rank
ROA -9.73%
ROE -22.29%
ROIC N/A
ROA(3y)-17.84%
ROA(5y)-30.62%
ROE(3y)-31.29%
ROE(5y)-51.12%
ROIC(3y)N/A
ROIC(5y)N/A
HCAT Yearly ROA, ROE, ROICHCAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 46.17%, HCAT is doing worse than 62.16% of the companies in the same industry.
In the last couple of years the Gross Margin of HCAT has remained more or less at the same level.
HCAT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.79%
GM growth 5Y-0.54%
HCAT Yearly Profit, Operating, Gross MarginsHCAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

More info and screens

2

2. Health

2.1 Basic Checks

HCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HCAT has been increased compared to 1 year ago.
Compared to 5 years ago, HCAT has more shares outstanding
Compared to 1 year ago, HCAT has a worse debt to assets ratio.
HCAT Yearly Shares OutstandingHCAT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
HCAT Yearly Total Debt VS Total AssetsHCAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

HCAT has an Altman-Z score of -1.28. This is a bad value and indicates that HCAT is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.28, HCAT is not doing good in the industry: 64.86% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.32 indicates that HCAT is not too dependend on debt financing.
HCAT has a Debt to Equity ratio (0.32) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Altman-Z -1.28
ROIC/WACCN/A
WACC8.68%
HCAT Yearly LT Debt VS Equity VS FCFHCAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M 500M

2.3 Liquidity

HCAT has a Current Ratio of 1.41. This is a normal value and indicates that HCAT is financially healthy and should not expect problems in meeting its short term obligations.
HCAT has a Current ratio (1.41) which is comparable to the rest of the industry.
A Quick Ratio of 1.41 indicates that HCAT should not have too much problems paying its short term obligations.
HCAT's Quick ratio of 1.41 is in line compared to the rest of the industry. HCAT outperforms 51.35% of its industry peers.
Industry RankSector Rank
Current Ratio 1.41
Quick Ratio 1.41
HCAT Yearly Current Assets VS Current LiabilitesHCAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

HCAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 225.00%, which is quite impressive.
HCAT shows a small growth in Revenue. In the last year, the Revenue has grown by 4.16%.
Measured over the past years, HCAT shows a very strong growth in Revenue. The Revenue has been growing by 21.32% on average per year.
EPS 1Y (TTM)225%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.33%
Revenue 1Y (TTM)4.16%
Revenue growth 3Y16.16%
Revenue growth 5Y21.32%
Sales Q2Q%3.5%

3.2 Future

The Earnings Per Share is expected to grow by 51.80% on average over the next years. This is a very strong growth
Based on estimates for the next years, HCAT will show a small growth in Revenue. The Revenue will grow by 7.95% on average per year.
EPS Next Y109.96%
EPS Next 2Y58.96%
EPS Next 3Y51.8%
EPS Next 5YN/A
Revenue Next Year4.11%
Revenue Next 2Y6.96%
Revenue Next 3Y7.95%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
HCAT Yearly Revenue VS EstimatesHCAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M
HCAT Yearly EPS VS EstimatesHCAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 -0.5 -1

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 20.12, which indicates a rather expensive current valuation of HCAT.
Based on the Price/Earnings ratio, HCAT is valued cheaply inside the industry as 89.19% of the companies are valued more expensively.
HCAT is valuated rather cheaply when we compare the Price/Earnings ratio to 29.62, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 13.80, which indicates a correct valuation of HCAT.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HCAT indicates a rather cheap valuation: HCAT is cheaper than 97.30% of the companies listed in the same industry.
HCAT's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.70.
Industry RankSector Rank
PE 20.12
Fwd PE 13.8
HCAT Price Earnings VS Forward Price EarningsHCAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HCAT Per share dataHCAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HCAT's earnings are expected to grow with 51.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.18
PEG (5Y)N/A
EPS Next 2Y58.96%
EPS Next 3Y51.8%

More info and screens

0

5. Dividend

5.1 Amount

HCAT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HEALTH CATALYST INC

NASDAQ:HCAT (2/21/2025, 8:25:12 PM)

After market: 5.23 0 (0%)

5.23

-0.16 (-2.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners89.34%
Inst Owner Change-97.49%
Ins Owners2.43%
Ins Owner Change-3.03%
Market Cap318.25M
Analysts80
Price Target9.99 (91.01%)
Short Float %3.39%
Short Ratio2.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.29%
Min EPS beat(2)-29.75%
Max EPS beat(2)48.34%
EPS beat(4)3
Avg EPS beat(4)688.94%
Min EPS beat(4)-29.75%
Max EPS beat(4)2661.67%
EPS beat(8)7
Avg EPS beat(8)590.79%
EPS beat(12)11
Avg EPS beat(12)407.66%
EPS beat(16)15
Avg EPS beat(16)318.1%
Revenue beat(2)0
Avg Revenue beat(2)-1.34%
Min Revenue beat(2)-1.89%
Max Revenue beat(2)-0.79%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-2.06%
Max Revenue beat(4)0.01%
Revenue beat(8)2
Avg Revenue beat(8)-0.67%
Revenue beat(12)5
Avg Revenue beat(12)-0.36%
Revenue beat(16)8
Avg Revenue beat(16)-0.06%
PT rev (1m)-14.18%
PT rev (3m)-14.85%
EPS NQ rev (1m)-7.8%
EPS NQ rev (3m)-13.69%
EPS NY rev (1m)-0.2%
EPS NY rev (3m)-11.6%
Revenue NQ rev (1m)-1.2%
Revenue NQ rev (3m)-1.22%
Revenue NY rev (1m)-0.16%
Revenue NY rev (3m)-0.29%
Valuation
Industry RankSector Rank
PE 20.12
Fwd PE 13.8
P/S 1.05
P/FCF N/A
P/OCF N/A
P/B 0.9
P/tB 7.2
EV/EBITDA N/A
EPS(TTM)0.26
EY4.97%
EPS(NY)0.38
Fwd EY7.25%
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS4.96
BVpS5.83
TBVpS0.73
PEG (NY)0.18
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.73%
ROE -22.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.17%
FCFM N/A
ROA(3y)-17.84%
ROA(5y)-30.62%
ROE(3y)-31.29%
ROE(5y)-51.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.79%
GM growth 5Y-0.54%
F-Score4
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.15%
Cap/Sales 4.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.41
Quick Ratio 1.41
Altman-Z -1.28
F-Score4
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)39.72%
Cap/Depr(5y)44.41%
Cap/Sales(3y)6.26%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)225%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.33%
EPS Next Y109.96%
EPS Next 2Y58.96%
EPS Next 3Y51.8%
EPS Next 5YN/A
Revenue 1Y (TTM)4.16%
Revenue growth 3Y16.16%
Revenue growth 5Y21.32%
Sales Q2Q%3.5%
Revenue Next Year4.11%
Revenue Next 2Y6.96%
Revenue Next 3Y7.95%
Revenue Next 5YN/A
EBIT growth 1Y35.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year254.26%
EBIT Next 3Y72.42%
EBIT Next 5YN/A
FCF growth 1Y66.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y96.84%
OCF growth 3YN/A
OCF growth 5YN/A